

SCHEMA(08/06/07)ELIGIBILITY

- Epithelial ovarian or peritoneal primary cancer
- FIGO Stage III with any gross (macroscopic or palpable) residual disease or FIGO Stage IV (06/26/06)

Randomization (cycle = 21 days):Arm I (standard chemotherapy)

Phase A Chemotherapy * day 1 every 21 days x 6 cycles
 Placebo (for bevacizumab) ** day 1 every 21 days beginning
 with cycle 2 x 5 cycles

↓

Re-registration

↓

Phase B Placebo (for bevacizumab) ** day 1 every 21 days cycles 7
 through 22 (06/26/06)

Arm II (concurrent bevacizumab)

Phase A Chemotherapy * day 1 every 21 days x 6 cycles
 bevacizumab ** day 1 every 21 days beginning with cycle 2 x 5
 cycles

↓

Re-registration

↓

Phase B Placebo (for bevacizumab) ** day 1 every 21 days cycles 7
 through 22 (06/26/06)

Arm III (extended bevacizumab)

Phase A Chemotherapy * day 1 every 21 days x 6 cycles
 bevacizumab ** day 1 every 21 days beginning with cycle 2 x 5
 cycles

↓

Re-registration

↓

Phase B bevacizumab ** day 1 every 21 days cycles 7 through 22
 (06/26/06)

*Paclitaxel 175mg/m² IV over 3 hours followed by Carboplatin AUC 6 IV over 30 minutes day 1 of cycles 1 through 6 only (Note: docetaxel 75mg/m² IV over 1 hour may be substituted for paclitaxel [see sections 2.65, 5.322, and 6.51].)

**bevacizumab / Placebo 15mg/kg IV day 1 of each cycle beginning with cycle 2

OUTCOME MEASURES

- Primary Endpoint:

- Overall Survival (OS)

- Secondary Endpoints:

- Progression-Free Survival (PFS)

- Response Rate (RR)

- Toxicity

- Quality of Life

- Translational Research - Please see Section 7.2 as well as Appendix VI (Specimen Procedures) and Appendix VII (Laboratory Procedures) for details regarding the specimen requirements and laboratory testing for this protocol.

Patients treated on this trial will not be eligible for therapy on clinical trials evaluating consolidation or maintenance therapy while on or off study.

TABLE OF CONTENTS (1-16-06)

	<u>PAGE</u>
1.0 <u>OBJECTIVES</u>	1
2.0 <u>BACKGROUND AND RATIONALE</u>	2
3.0 <u>PATIENT ELIGIBILITY AND EXCLUSIONS</u>	15
4.0 <u>STUDY MODALITIES</u>	20
5.0 <u>TREATMENT PLAN AND ENTRY/RANDOMIZATION PROCEDURE</u>	37
6.0 <u>TREATMENT MODIFICATIONS</u>	45
7.0 <u>STUDY PARAMETERS</u>	57
8.0 <u>EVALUATION CRITERIA</u>	65
9.0 <u>DURATION OF STUDY</u>	72
10.0 <u>STUDY MONITORING AND REPORTING PROCEDURES</u>	73
11.0 <u>STATISTICAL CONSIDERATIONS</u>	78
12.0 <u>BIBLIOGRAPHY</u>	92

SUGGESTED PATIENT INFORMED CONSENT

APPENDIX I	-FIGO Stage Grouping for Primary Carcinoma of the Ovary (1985)
APPENDIX II	-Glossary of Terms
APPENDIX III	-NCI Standard Language Involving Agent(s) Covered by a Clinical Trials Agreement or a Cooperative Research and Development Agreement
APPENDIX IV	-GOG Web-Based Registration and Randomization
APPENDIX V	-Anaphylaxis Precautions
APPENDIX VI	-Specimens Procedures for GOG-0218 (06/26/06)
APPENDIX VII	-Laboratory Procedures for GOG-0218 (06/26/06)
APPENDIX VIII	-Logistical Guidelines for CTSU for GOG-0218 (06/26/06) (08/06/07)

1.0 OBJECTIVES

This is a phase III randomized study to evaluate new treatment programs for patients with International Federation of Gynecologic Oncology (FIGO, Appendix I) stages III and IV, epithelial ovarian and peritoneal primary cancer. (06/26/06) (08/06/07)

1.1 Primary Objectives

- 1.11 To determine if the addition of 5 concurrent cycles of bevacizumab to 6 cycles of standard therapy (carboplatin and paclitaxel) [Arm II] reduces the death rate when compared to 6 cycles of standard therapy alone [Arm I] in women with newly diagnosed stage III (with any gross residual disease) and stage IV, epithelial ovarian and peritoneal primary cancer. (06/26/06) (08/06/07)
- 1.12 To determine if the addition of 5 concurrent cycles of bevacizumab (06/26/06) plus extended bevacizumab for 16 cycles beyond the (06/26/06) 6 cycles of standard therapy (carboplatin and paclitaxel) [Arm III] reduces the death rate when compared to 6 cycles of standard therapy [Arm I] in women with newly diagnosed stage III (with any gross residual disease) and stage IV, epithelial ovarian and peritoneal primary cancer. (06/26/06) (08/06/07)

1.2 Secondary Objectives

- 1.21 In the event that both Arm II and Arm III regimens are superior to the Arm I regimen with respect to overall survival, to determine whether the Arm III regimen reduces the death rate when compared to the Arm II regimen.
- 1.22 To determine whether the Arm II or Arm III regimen increases the duration of progression-free survival (PFS) when compared with the Arm I regimen.
- 1.23 To compare each of the experimental regimens to the Arm I regimen with respect to the incidence of severe toxicities or serious adverse events.
- 1.24 To determine the impact on Quality of Life (QOL, as measured by the **FACT-O TOI**) following treatment with the above regimens.

1.3 Translational Research Objectives

- 1.31 To assess the relationship between angiogenic markers and clinical outcome including tumor response, progression-free survival and overall survival in patients randomized to standard cytotoxic chemotherapy (paclitaxel and carboplatin) without bevacizumab, with concurrent bevacizumab or with extended bevacizumab.
- 1.32 To assess the predictive value of a set of genes whose expression correlates with survival of patients with stage III (with any gross residual disease) and stage IV, epithelial ovarian and peritoneal primary cancer. (06/26/06) (08/06/07)

2.0 BACKGROUND AND RATIONALE

2.1 Standard Management of Advanced Ovarian and Peritoneal primary Carcinoma

After initial surgical diagnosis, staging and cytoreduction, the standard primary systemic chemotherapy for women with advanced epithelial ovarian and peritoneal primary cancer consists of chemotherapy with a platinum and taxane combination,^{1,2} usually carboplatin³⁻⁶ and paclitaxel. While significant advances have been made in patient management, this disease still carries the highest fatality to case ratio for all gynecologic malignancies diagnosed in the United States. It is estimated that in 2004, 25,580 new cases will have been diagnosed and 16,090 women will have died of the disease.⁷ Over the past two decades, there have been only modest improvements in overall 5-year survival, and while 5-year survival has increased steadily from 30% to 50% overall, it has improved by only 5%, from 20% to only 25% for women with advanced-stage tumors. Clearly improvements are needed in primary therapeutic strategies.

2.2 New Therapeutic Strategies to Improve Outcomes

GOG-0182-ICON5 was a 5-arm randomized clinical trial comparing standard therapy (carboplatin and paclitaxel) with four investigational arms incorporating gemcitabine, topotecan and liposomal doxorubicin, either in combination or in sequence with paclitaxel and carboplatin. Major ovarian cancer clinical trials groups throughout the world participated in this study, including the MRC ICON investigators in the United Kingdom, European Institute of Oncology in Italy, and the Australia-New Zealand GOG Consortium. This international collaboration provided a unique opportunity to accrue large numbers of patients in a timely manner which facilitated the simultaneous evaluation of multiple agents in a prospective randomized trial. With international participation, accrual exceeded 1,200 patients per year, and the trial reached its targeted accrual goal within four years of activation.

While the results of GOG-0182-ICON5 will help establish optimum chemotherapy for previously untreated patients with advanced ovarian and peritoneal primary cancer, the next generation of clinical trials will explore the impact of molecular targeted therapies in conjunction with chemotherapy. In particular, growth factor signal transduction inhibitors and anti-angiogenic agents as single agents and in combination with cytotoxic drugs are currently undergoing phase I and II trials in women with these tumors. Many of these agents have been shown to have cytostatic effects and have shown synergy with chemotherapy in experimental models of human cancer. In addition, since it is postulated that such biologic agents may also have a role in maintenance therapy, the general approach in phase III trials will be the evaluation of the impact on outcome of active biologic agents in combination with standard cytotoxic therapy plus or minus extended single agent administration, compared with standard cytotoxic therapy alone, in patients with advanced disease.

2.3 Rationale for Angiogenesis -Targeted Therapeutics

Angiogenesis is one of the cardinal processes leading to invasion and metastasis of solid tumors. The angiogenic-signaling pathway may be triggered by the release of angiogenic promoters such as vascular endothelial growth factor (VEGF) from tumor cells into the local microenvironment. There is accumulating evidence that angiogenesis plays a central role in ovarian cancer disease progression and prognosis.⁸⁻¹³ Given that a direct relationship has been demonstrated between the expression of biomarkers of angiogenesis and the behavior of epithelial ovarian cancer, it would seem implicit that pharmacological inhibitors of angiogenesis could arrest tumor progression.¹⁴⁻¹⁷ Neutralizing anti-VEGF monoclonal antibodies have demonstrated therapeutic activity in a variety of pre-clinical solid tumor models.^{18,19}

2.4 Role of Bevacizumab, an Anti-VEGF Monoclonal Antibody, in Epithelial Ovarian and Peritoneal primary Cancer Therapy

Bevacizumab is a recombinant humanized version of a murine anti-human VEGF monoclonal antibody, named rhuMab VEGF. Bevacizumab has been advanced into clinical development for use as a single agent to induce tumor growth inhibition in patients with solid tumors and for use in combination with cytotoxic chemotherapy to delay the time to disease progression in patients with metastatic solid tumors.²⁰

A current phase II trial of single agent bevacizumab for patients with recurrent epithelial ovarian and peritoneal primary cancer having received one to two prior chemotherapy regimens is ongoing in the GOG (GOG-0170-D). Accrual to this two-stage designed trial was completed early in September 2004. The trial advanced into its second accrual stage based on objective responses reported in the first cohort of 28 patients. The interim preliminary analysis revealed that approximately 25% demonstrated objective responses by RECIST criteria, and approximately 1/3 of patients were on treatment without evidence of progression at 6 months. This appeared to be an extremely unusual observation for a compound presumed to be at best cytostatic when administered as a single agent. The final analysis of this trial is planned for the first quarter of 2005.

2.5 Experience with Combination Bevacizumab - Cytotoxic Therapy

Evidence from pre-clinical studies and recent phase II and III clinical trials in other solid tumors has demonstrated enhanced anti-tumor activity of traditional cytotoxic regimens, when combined with bevacizumab. For example, Devore and colleagues reported on a three-arm phase II randomized trial of carboplatin/paclitaxel at with or without bevacizumab (7.5 mg/kg or 15 mg/kg dose levels) every 21 days until disease progression, in 99 patients with stages IIIB and IV non-small cell lung cancer.²¹ Response rates were 21.9 percent (7/32 patients) in the low dose and 42.9 percent (14/35 patients) in the high dose bevacizumab combination arms, compared to a response rate of 31.3 percent (10/32 patients) in the chemotherapy alone arm. A phase II/III trial in this patient population has been conducted by ECOG; the final analysis of this study is pending.

More importantly, a recently reported phase III trial, AVF2107, of over 800 previously untreated patients with previously untreated metastatic colorectal cancer randomized to receive either bevacizumab for one year plus the Saltz chemotherapy regimen (5-FU/Leucovorin/CPT-11, IFL) or the Saltz regimen plus placebo for one year met its primary endpoint of improving overall survival.²² The magnitude of benefit observed far exceeded what the study was designed to demonstrate. The trial also met the secondary endpoints of progression-free survival, response rate, and duration of response (see table below).

	IFL/ bevacizumab (n = 403)	IFL/ placebo (n = 412)	Hazard Ratio (p-Value)
Response Rate	44.9%	34.7%	(0.0029)
Median TTP	10.6 months	6.2 months	(0.00001)
Median Survival	20.3 months	15.6 months	0.65 (0.00003)

Bleeding, thrombosis, asymptomatic proteinuria and hypertension were identified in phase II studies as possible safety events, but only Grade 3 hypertension and arterial thrombosis events were clearly increased in this phase III study.

Preliminary results from a more recent, large, randomized phase III trial for patients with advanced colorectal cancer who had previously received treatment show that those who received bevacizumab in combination with an oxaliplatin regimen known as FOLFOX4 (oxaliplatin, 5-fluorouracil and leucovorin) had a significantly prolonged survival over patients who received FOLFOX4 alone. The Data Monitoring Committee overseeing the trial, known as E3200, recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of demonstrating improved overall survival, which was 17% longer in the bevacizumab arm. Specifically, the median overall survival in the bevacizumab plus FOLFOX4 arm was 12.5 months compared to 10.7 months for patients treated with FOLFOX4 alone. There was a 26 percent reduction in the risk of death (hazard ratio of 0.74) for patients in this study who received bevacizumab plus FOLFOX4 compared to those who received FOLFOX4 alone. Treatment toxicities observed in this study were consistent with those adverse effects observed in other clinical trials in which bevacizumab was combined with chemotherapy. These included hypertension and bleeding as more predominant in the bevacizumab arm.²³

Multiple phase I-III trials, such as those cited above, have demonstrated the safety and tolerability of bevacizumab with traditional schedules and dosing of carboplatin and paclitaxel.

2.6 Rationale for Clinical Trial Design

Bevacizumab was selected for evaluation in combination with standard chemotherapy based on preliminary phase II single agent data obtained in patients with recurrent epithelial ovarian and peritoneal primary cancers (see Section 2.4) and results from a

phase III clinical trial in patients with metastatic colorectal cancer demonstrating a survival benefit to patients receiving bevacizumab with standard cytotoxic chemotherapy compared with patients receiving standard chemotherapy alone (see Section 2.5). Based on the mechanism of action of bevacizumab, there may be benefit of extended therapy with this agent until disease progression, in extending PFS or OS in this patient population. However, it is unclear whether additional benefit of bevacizumab beyond the general duration of standard primary chemotherapy exists. Therefore, two experimental arms were selected to compare with standard cytotoxic chemotherapy with paclitaxel and carboplatin: one incorporating 5 cycles of bevacizumab (concurrent bevacizumab) and the other with bevacizumab for an additional 16 cycles after completion of chemotherapy with paclitaxel and carboplatin (06/26/06) (extended bevacizumab).

This is a double-blind, placebo-controlled phase III trial in order to preserve the integrity of the progression-free survival and overall survival endpoints by eliminating biases in disease assessment monitoring, the declaration of disease progression and the institution/selection of future therapies. Therefore, it is understood that investigators, patients and research personnel will not know whether or not patients have received bevacizumab or placebo. Because of the intent-to-treat analysis, this rule applies to patients who enter the study and then are later found to be ineligible. The only indication for unblinding to treatment arm is a serious adverse event in which it is determined by the Study Chair that unblinding would improve patient safety. The justification for maintaining the blind even after disease progression is the absence of evidence that such knowledge would provide increased benefit. For example, there is no evidence that prior exposure to bevacizumab would exclude subsequent use/benefit of bevacizumab or other VEGF targeted agents. (08/06/07)

2.61 Study Population

A study population limited to those patients with stage III-suboptimal and stage IV (06/26/06) tumors was initially selected because this group carries the poorest prognosis of those with advanced disease and would allow conservation of sample size needed to demonstrate a survival benefit associated with bevacizumab therapy. However, the accrual rate through the first 18 months of study was less than half that projected. A systematic survey of the study sites revealed that the majority of patients with epithelial ovarian cancer or primary peritoneal cancer undergoing up front surgery are optimal (have no more than 1 cm maximal diameter residual tumor implants) and that a major obstacle to enrollment has been the exclusion of such patients. Furthermore, the results of the trial would be better generalized to the population at large with epithelial ovarian and primary peritoneal cancers with the inclusion of the largest subset of these patients. That being said, a decision was made to limit enrollment of patients with stage III optimal cancers to only those with macroscopic residual disease at the completion of initial surgery; this is because those with no gross (macroscopic or palpable) residual disease are felt to be at too low a risk for relapse and death to justify their inclusion (see revisions to section on Statistical Considerations). (08/06/07)

2.62 Sample Size Considerations

The sample size of the proposed study was estimated with overall survival (OS) as the primary endpoint, while taking steps to protect the integrity of progression-free survival (PFS) as a secondary endpoint. At the recently held 3rd International Ovarian Cancer Consensus Conference, September 2004, in Black Forest, Germany, an agreement was reached that PFS is a reproducible surrogate of overall survival in this population.²⁴ In keeping with this agreement, there will be a planned final analysis of PFS incorporated into the statistical analysis plan that is being submitted to the FDA under the Special Protocol Assessment process.

2.63 Optimum Number of Cytotoxic Chemotherapy Cycles

It has become common practice to administer six to eight cycles of initial chemotherapy in phase III clinical trials for patients with advanced-stage ovarian cancer. The optimal number of cycles has not been defined, but there is no evidence that more than 4 cycles is associated with an improvement in long-term outcomes. Length of therapy has not been prospectively evaluated with a combination of platinum and paclitaxel. From available data, it is reasonable to conclude that the absolute number of cycles within a clinically relevant range of between 6 and 8 is unlikely to have a measurable impact on long-term disease control. At present, there are no prospective data to indicate that dose intensity, cumulative dose delivery, or number of cycles has an impact on long-term outcomes following primary therapy with platinum and paclitaxel. There is, however, evidence of increased risk of severe adverse effects of treatment with the combination of paclitaxel and carboplatin beyond the traditional 6 cycles. These effects include cumulative platelet toxicity and increased risks of severe hypersensitivity, particularly related to carboplatin, as well as increased risk of high Grade neuropathy related to paclitaxel. The above counterbalancing factors serve as the rationale for 6 cycles of induction chemotherapy in the current trial.

2.64 Wound Healing Issues

2.641 Delay of Initial Treatment with bevacizumab

Because of the concern of potential wound complications related to bevacizumab, in this trial bevacizumab/placebo therapy will begin at the start of cycle number 2 of carboplatin and paclitaxel combination chemotherapy.

2.642 Management of Incisions Healing by Secondary Intention

It is not uncommon for patients recovering from initial cytoreductive surgery for advanced epithelial ovarian or primary peritoneal cancer to have granulating incisions healing by secondary intention. Excluding such patients would therefore be discriminatory, and conclusions of this trial could not be validly generalized to the population with these tumors. If inhibition of further healing in patients with uncomplicated incisions healing by secondary intention occurred in patients receiving bevacizumab, it would be extremely unlikely for such

interruption in the healing process to lead to CTC Grade 3 or Grade 4 events (e.g. requirement of additional surgery for failure to heal or wound re-opening, infection requiring systemic antibiotics). Therefore, patients with uncomplicated wound separations healing by secondary intention without evidence of fascial dehiscence, active infection or fistula will be eligible to participate in this trial and receive bevacizumab/placebo. As an additional safeguard for such patients, weekly wound examinations will be required until complete wound closure, with specific chart and case report form documentation. In the event of deterioration, bevacizumab/placebo would be discontinued. (06/26/06)

2.65 Selected Substitution of Docetaxel for Paclitaxel

Publication of results from GOG Protocol 0111²⁵ and a confirmatory European trial²⁶ led to adoption of paclitaxel and carboplatin as the standard primary therapy for patients with advanced epithelial and peritoneal primary cancer. However, it is estimated that on the order of 5% of patients in the population eligible for participation in the current trial will develop peripheral neuropathy or refractory acute hypersensitivity infusion reactions which would necessitate discontinuation of paclitaxel.

Docetaxel is a novel taxane with reduced potential for neurotoxicity compared with paclitaxel. In addition, docetaxel has been safely substituted for paclitaxel in patients experiencing severe acute hypersensitivity to paclitaxel refractory where re-challenge is either unsuccessful or deemed unsafe.

With regard to efficacy, there is evidence that docetaxel is an alternative treatment option to paclitaxel for patients with epithelial ovarian and peritoneal primary cancer. Docetaxel has been combined with cisplatin or carboplatin extensively in phase II and III clinical trials. These studies have demonstrated activity in a variety of tumor types (non-small cell lung, breast, head and neck, bladder, gastric, and gynecologic malignancies) and show that combinations of these drugs are safe and feasible.²⁷⁻⁵³ Docetaxel has substantial activity against platinum-refractory ovarian carcinoma⁵⁴ and is also active as primary therapy in ovarian cancer.^{30,43,49,51} A phase III randomized trial (SCOTROC) of docetaxel and carboplatin versus paclitaxel and carboplatin in patients with advanced epithelial ovarian cancer has recently been published.⁵⁰ In this trial, patients received carboplatin at an AUC of 5 with either docetaxel at 75 mg/m² 1-hour IV infusion or paclitaxel at 175 mg/m² 3-hour IV infusion. Results of this trial demonstrated no significant difference in median progression-free survival (15.0 months versus 14.8 months), two year overall survival (64.2% versus 68.9%) or objective tumor response (58.7% versus 59.5%) for the combination of docetaxel and carboplatin versus the combination of paclitaxel and carboplatin, respectively. While docetaxel and carboplatin produced more neutropenia (Grade 3-4 neutropenia 94% for docetaxel and carboplatin versus 84% for paclitaxel and carboplatin, $p < .001$) and neutropenic complications than treatment with paclitaxel-carboplatin, the docetaxel and carboplatin regimen was

significantly less neurotoxic (Grade ≥ 2 neurosensory toxicity in 11% for docetaxel and carboplatin versus 30% for paclitaxel and carboplatin, $p < .001$).

The results of the SCOTROC trial have led many oncologists to select substitution of docetaxel for paclitaxel in first line therapy for patients with advanced epithelial and peritoneal primary cancer. Thus, in order to optimize cytotoxic therapy in all arms of the current trial, reduce the likelihood of protocol violations and avoid imbalances in the type of taxane utilized in each treatment arm, in the current trial docetaxel will be selectively substituted for paclitaxel in circumstances in which peripheral neuropathy or hypersensitivity warrants discontinuation of paclitaxel (Section 6.51 and Section 6.62, respectively).

2.66 Post-Remission Therapy

It is expected that all of the chemotherapy regimens employed in this trial will achieve an overall response rate of greater than 75%. However, as many as 90% of patients with stage III-suboptimal and stage IV (06/26/06) epithelial ovarian and peritoneal primary cancer in clinical complete remission will ultimately recur and die of disease. Therefore, a number of strategies are under active consideration to delay or prevent recurrence. Among these strategies include “consolidation” treatment with cytotoxic, hormonal, or biologic targeted agents. For example, recent data have revealed that continuation of single-agent paclitaxel on a monthly schedule for 12 cycles significantly extended progression-free survival.⁵⁵ Certainly consolidation therapy has been implemented variably in clinical practice outside clinical trials with the decision based on physician and patient preference, with no evidence that overall survival is influenced by either treatment of patients in complete clinical remission or for that matter, at the time of clinical disease progression.

Due to the lack of evidence that any current consolidation approach is associated with an improvement in overall survival, and our desire to preserve the integrity of the progression-free interval as a secondary endpoint of clinical importance, the current trial design will control for the potential use of consolidation therapies, including agents unique to the experimental regimen, as well as the potential for investigator assessment bias. In order to accomplish this goal, the arms will be placebo-controlled. Based on the mechanism of action of bevacizumab, there may be benefit of extended therapy with this agent, justifying the inclusion of an extended therapy arm in the current trial. Specifically, a total of 22 cycles (06/26/06) of treatment was chosen since it approximates the 15 months (06/26/06) median PFS in this population of women with stage III-suboptimal and stage IV (06/26/06) epithelial and peritoneal primary cancer, based on data from recent GOG phase III trials (see Section 11.0). While it was considered important for the placebo control to be maintained for this entire duration in all three arms of the trial, at the same time extending a placebo beyond 15 months was felt to be impractical, unethical and cost-prohibitive. Finally, patients treated on this trial will not be eligible for therapy on clinical trials evaluating consolidation or maintenance therapy while on or off study.

2.67 Role of Secondary Surgery

Continued uncertainty exists as to whether second-look surgical procedures contribute to the overall management of patients with ovarian cancer. Some investigators and institutions do not recommend a second-look operation whereas other investigators feel that, in some patients, a second-look procedure may be useful to identify patients with small-volume residual disease who are candidates for additional treatment. The uncertain benefit of second-look surgery has been reflected in current treatment guidelines, where it has been designated as an optional procedure (NCCN). In community practice outside of clinical trials, the frequency of second-look surgery has declined. The non-uniform application of second-look surgery and the ability to document “sub-clinical” residual disease has the potential for confounding primary endpoints on this clinical trial, such as determination of the PFS. In the absence of clear evidence that this procedure provides benefit, second-look surgery for patients in clinical complete remission will not be permitted on the current study.

Based on results from GOG-0152 demonstrating that interval secondary cytoreductive surgery did not improve progression-free or overall survival in patients with advanced disease who had previously undergone maximal primary cytoreduction,⁵⁶ and the potential for increased surgical morbidity from delayed wound healing in patients who undergo major surgical procedures while on treatment with bevacizumab, interval cytoreductive surgery will not be permitted for patients enrolled on the current trial.

2.68 CA-125 as a Biologic Marker of Progressive Disease

Serum levels of CA-125, a tumor-associated glycoprotein antigen, are elevated in 80% of patients with epithelial ovarian cancer.⁵⁷ CA-125 has been monitored, often on a frequent basis, to verify response to therapy, presence of residual disease, and as early evidence of recurrence. However, CA-125 is not entirely tumor specific, and can be elevated in a variety of benign conditions, such as endometriosis, uterine fibroids, and pelvic inflammation; this is particularly true in pre-menopausal women. In addition, levels of CA-125 can be discordant with tumor response, both as false-positive and false-negative trends; the influence of biologic agents on these inaccuracies is unclear. Nonetheless, because imaging modalities such as contrast computed tomography appear to be relatively insensitive in detecting disease progression, it has been standard practice for patients and physicians interpret a progressive rise in CA-125 post-therapy as evidence of recurrent or progressive disease, and will make therapeutic decisions based solely on the CA-125. This has complicated the assessment of PFS in prior randomized trials, as patients will receive new therapy prior to clinical documentation of progressive disease on the basis of physical examination or radiographic findings. The current randomized trial will employ a conservative formula to define progressive disease based on serial elevation of CA-125⁵⁸⁻⁶² (in addition to other standard definitions in the management of solid tumors), but only following completion of initial chemotherapy. Although imperfect, it is preferable to apply uniform criteria that include CA-125 rather than absorb uncharacterized events that would compromise the secondary endpoint of PFS. Progression during the period of cytotoxic chemotherapy will

require radiographic or physical confirmation.

2.7 Quality of Life (QoL)

This trial will help determine if anti-VEGF therapy, when combined with standard chemotherapy, prolongs OS and PFS after suboptimal cytoreductive surgery of epithelial ovarian and peritoneal primary cancer. In addition, this study will determine the optimal schedule of anti-VEGF therapy. Patient-reported outcomes may differ when anti-VEGF therapy is added to standard paclitaxel and carboplatin chemotherapy. Specifically, the primary objective of measuring QoL in this trial is to determine if the addition of anti-VEGF therapy reduces disease related symptoms (improves QoL) more quickly and for more prolonged periods of time than chemotherapy alone. In addition, other objectives of measuring QoL include determining if anti-VEGF therapy alters QoL as a result of treatment related toxicity not captured through traditional physician-reported measures.

Preliminary data from GOG Protocol 0170-D suggest that bevacizumab may, among responders, not only reduce tumor volume as measured through traditional disease response monitoring, but may also clear ascites and pleural effusions leading to reduced abdominal bloating and pain thus improving QoL. Indeed, VEGF appears to be obligatory for ascites formation by increasing vascular permeability.⁶³ Thus, neutralization of VEGF activity could perhaps dramatically improve QoL after just one or two doses of bevacizumab by reducing malignant ascites formation. Moreover, since taxanes have anti-angiogenesis activity, it is hypothesized that a combination of bevacizumab and paclitaxel could be synergistic.⁶⁴ Unfortunately, QoL was not closely monitored in GOG Protocol 0170-D and future trials such as the current clinical trial studying bevacizumab in ovarian cancer require QoL measures to evaluate these important endpoints.⁶⁵

Since most women with stage III-suboptimal and stage IV epithelial ovarian or primary peritoneal (06/26/06) cancer will succumb to their malignancy and since many regimens have similar efficacy, differences in QoL may help determine the optimal treatment regimen in this setting. In addition, systematic documentation of QoL among those enrolled onto this trial may assist in providing information to future non-trial patients regarding the expected effects of therapy as they make their treatment choices. To date, four completed phase III studies in the upfront treatment of ovarian cancer have implemented QoL outcome measures in their study design, and in every instance QoL was helpful in determining the best regimen. For example, OV.10 established the benefit of paclitaxel in treating ovarian carcinoma,^{26,66} the AGO trial established the benefit of carboplatin,⁶⁷ and the SCOTROC trial established the role of docetaxel⁵⁰ and in all of these studies QoL was an important endpoint. More recently, GOG-0152 was the first prospective trial to study QoL in ovarian cancer performed in the GOG. This study included (06/26/06) patients similar to the current study and demonstrated the feasibility of obtaining high quality QoL data from this population within this cooperative group.⁶⁸ GOG-0152 again illustrated the critical importance of measuring QoL. This study showed that endpoints useful in evaluating optimal therapies in the upfront management of ovarian cancer may be missed if only physician reported endpoints are measured. For example, this study found important difference in neurotoxicity between regimens by measuring QoL and demonstrated that baseline QoL (as measured by the FACT-O) was prognostic of overall survival. Importantly, the

recently completed study, GOG-0182, which was the predecessor to the currently proposed study, did not contain a QoL component. If this trial shows no difference in the anti-tumor activity between the six regimens studied in this clinical trial, the opportunity to pick the best regimen will be missed because QoL was not measured.

In the current trial, QoL will be assessed using the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary (FACT-O TOI).^{69,70} This 26-item summary score captures the FACT-G QOL dimensions of Physical Well-Being (7 items), Functional Well-Being (7 items), and the Ovarian Cancer Subscale (12 item). By combining these three subscales, one is assured of capturing the full range of physical aspects of QOL in advanced ovarian cancer, including pain, fatigue, abdominal symptoms and functional status. By combining questions GP4, O1, and O3, which assess abdominal pain, swelling and cramps respectively, a comprehensive patient reported assessment of disease related abdominal symptoms including ascites can be evaluated. Also, the abdominal pain module piloted in GOG Protocol 0172 will be included.

The timing of the QoL assessments is critical to capture data useful in discriminating subtle differences between regimens. This is complicated by the fact that the acute effects of cytotoxic therapy may cause a decrease in QoL. In order to capture early difference in QoL as a result of anti-angiogenesis therapy with bevacizumab, assessment time points during this trial will be weighted toward the early part of this study. In addition, since some subjects may only complete a few cycles of therapy, it is important to have early assessment points. Finally, in order to avoid the confounding effects of acute chemotherapy related toxicity, questionnaires will be completed just before (21 days after the last dose) the next cycle of chemotherapy and focus on QoL within the last seven days. Thus, assessments will be made:

1. Prior to cycle 1 (t = 0 weeks)
2. Prior to cycle 4 (after 3 doses of chemotherapy and 2 doses of bevacizumab/placebo, t= 9 weeks), to assess immediate changes in QoL
3. Prior to cycle 7 (after 6 doses of chemotherapy and 5 doses of bevacizumab/placebo, t= 18 weeks) to assess intermediate changes in QoL
4. Prior to cycle 13 (t= 36 weeks), 6 months after chemotherapy
5. Prior to cycle 21 (t= 60 weeks), completion of study therapy
6. 6 months after completion of study therapy (t= 84 weeks)

2.8 Translational Research Related to Anti-VEGF Therapy

2.81 Markers of Angiogenesis

Angiogenesis is one of the cardinal processes leading to invasion and metastasis of solid tumors. There are more than 19 known angiogenic growth factors and at least 30 known angiogenesis inhibitors in the body, and more than 300 exogenous angiogenesis inhibitors have been discovered to date. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are among the most well studied angiogenic growth factors. In tumors, angiogenesis has been studied by quantifying the tumor blood micro-vessel density (MVD) determined immunohistochemically using antibodies to CD31, a protein expressed on the surface of vascular endothelial cells. MVD has been

shown to predict the response of gastric adenocarcinomas to taxane-based therapy.⁷¹ In addition to MVD, most angiogenesis studies also evaluate VEGF, which has been shown to promote neovascularization and stimulate endothelial cell survival.⁷² VEGF levels were also found to correlate with MVD in endometrial and cervical, but not ovarian cancers.^{73,75} In ovarian cancer, higher VEGF levels, but not MVD, were found to significantly correlate with decreased patient survival.⁷⁴ Multivariate analysis demonstrated that VEGF was an independent prognostic indicator of overall survival,⁷⁴ while the prognostic significance of MVD alone for ovarian cancer was less strong.^{74,76}

Immunohistochemistry will be utilized to evaluate the expression of CD-31 and VEGF in previously untreated primary or metastatic tumor tissue. Expression of these angiogenic markers will be examined in conventional unstained tumor sections compared with tissue micro arrays (TMAs). An analysis will be undertaken to assess the relationship between tumor tissue expression of angiogenic markers and clinical outcome including tumor response, progression-free survival and overall survival in this patient population in the TMAs created for GOG-0218 if appropriate. If not, conventional unstained tissue sections will be used to examine the relationship between the angiogenic markers and clinical outcome in patients participating in this randomized treatment protocol. Immunoassays will be performed to quantify the concentration of angiogenic markers including VEGF in serum and plasma. Plasma is being added as an optional specimen for GOG-0218 based on recent observations from GOG-0229B and GOG-0231B suggesting that the pre-treatment concentration of VEGF in plasma not serum was associated with progression-free survival and overall survival in patients with persistent or recurrent endometrial cancer and in patients with persistent or recurrent leiomyosarcoma of the uterus (manuscripts in preparation). The exact choice of biomarkers to be evaluated and assays to be performed in tumor, serum and plasma specimens will be reevaluated based on evolving data in the field. (1-16-06) (06/26/06)

The GOG has embarked on a programmatic examination of angiogenic markers as predictors of clinical outcome including tumor response and survival in ovarian and cervical cancer. The first part of this plan incorporated exploratory translational research objectives into Phase II (GOG-0170D, GOG-0229B and GOG-0231-B) and Phase III (GOG-0157, GOG-0175 and GOG-0191) treatment protocols, a pilot protocol (GOG-9911) and a GOG Tissue Bank project. The laboratory data for these studies will continue to be analyzed, reported and published during the next few years. The second part of this plan will incorporate research hypotheses generated from these exploratory studies into definitive translational research objectives that can be tested and validated in randomized phase III treatment protocols activated or under development in ovarian cancer and cervical cancer including GOG-0198, GOG-0212, GOG-0213, GOG-0218, and GOG-0219. At the appropriate time, the current translational research objectives in GOG-0218 will be amended to incorporate a definitive translational research objective regarding angiogenic markers that can be tested and validated using the specimens submitted for this protocol. A summary of the relevant laboratory data will also be provided to establish the background and rationale for that amendment.

2.82 Genomic Analysis

The genomic research component of this protocol will focus on the refinement and validation of genes whose expression predict for survival in patients with advanced stage ovarian cancer. Despite the fact that 80% of advanced ovarian cancers (stages III/IV) respond to primary treatment with surgery and chemotherapy, the disease usually recurs and is ultimately fatal. Though most patients die within two years of diagnosis, a subset of patients, even with clinically and morphologically indistinguishable diseases, develop a more chronic form of ovarian cancer, and may survive five years or more with treatment. It is possible that patients with indolent cancer should be monitored and treated differently from patients with rapidly progressing ovarian cancer. At this point, clinicians do not have the tools to predict the clinical course of the disease at the time of initial diagnosis.

Transcription profiling is a large-scale gene-expression analysis-technology, which has been widely used to identify differentially expressed genes and molecular signatures in many biological processes.⁷⁷⁻⁷⁹ In the past five years, over 600 manuscripts on expression profiling of cancers using microarray technology have been published, illustrating the recognized utility of this approach in exploring questions of tumor biology and clinical correlates. The principles of class prediction and class discovery as they apply to the molecular classification of human cancers were exemplified by Golub et al., who used oligonucleotide micro arrays to monitor gene expression in acute leukemias as a test case.⁷⁸ Class prediction identified and validated a subset of informative genes whose expression was highly correlated with previously defined classes. Further, subsequent studies have utilized these approaches to provide proof of the “molecular profiling principle” as well as to gain novel insights into clinical cancer problems. Using a specialized, lymphoid cell-specific cDNA microarray, Alizadeh et al. performed expression profiling of diffuse large B-cell lymphomas and identified two molecularly distinct forms of this malignancy that correlated with overall survival.⁷⁷

We hypothesize that transcription profiling will provide us with gene signatures for advanced stage ovarian cancer patients who are likely to develop aggressive recurrent disease and shortened survival, and thus may need to be treated with unconventional regimens.

Thus, these new discoveries and technologies provide an ideal opportunity to determine the molecular and biochemical basis for the survival of patients with stage III-suboptimal and stage IV (06/26/06) epithelial ovarian and peritoneal primary cancers.

2.9 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) or Similar Leukoencephalopathy Syndrome

RPLS or clinical syndromes related to vasogenic edema of the white matter have been rarely reported in association with bevacizumab therapy (< 1%). Clinical presentations

are variable and may include altered mental status, seizure and cortical visual deficit. HTN is a common risk factor and was present in most (though not all) patients on bevacizumab who developed RPLS. MRI scans are key to diagnosis and typically demonstrate vasogenic edema (hyper intensity in T2 and FLAIR images and hypo intensity in T1 images) predominantly in the white matter of the posterior parietal and occipital lobes; less frequently, the anterior distributions and the gray matter may also be involved. RPLS should be in the differential diagnosis in patients presenting with unexplained mental status change, visual disturbance, seizure or other CNS findings. RPLS is potentially reversible, but timely correction of the underlying causes, including control of BP and interruption of the offending drug, is important in order to prevent progression to irreversible tissue damage. **(Date 2006)**

2.10 Inclusion of Women and Minorities

The Gynecologic Oncology Group and GOG participating institutions will not exclude potential subjects from participating in this or any study solely on the basis of ethnic origin or socioeconomic status. Every attempt will be made to enter all eligible patients into this protocol and therefore address the study objectives in a patient population representative of the entire epithelial ovarian and peritoneal primary cancer population treated by participating institutions.

3.0 PATIENT ELIGIBILITY AND EXCLUSIONS

3.1 Eligible Patients

- 3.11 Patients with a histologic diagnosis of epithelial ovarian cancer or peritoneal primary carcinoma, FIGO stage III (Appendix I) with any gross (macroscopic or palpable) residual disease or FIGO stage IV (Appendix I), (06/26/06) defined surgically at the completion of initial abdominal surgery and with appropriate tissue available for histologic evaluation. The minimum surgery required was an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking. If additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the GOG Surgical Procedures Manual (<https://www.gog.fccc.edu/manuals/pdf/surgman.pdf>). However, the surgeon is not required to have performed all of the items contained in this section of the GOG Surgical Procedures Manual. Those patients with stage III cancer in which the largest maximal diameter of any residual tumor implant at the completion of this initial surgery is no greater than 1 cm will be defined as “optimal;” all others will be defined as “suboptimal.” (08/06/07)
- 3.12 Patients with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.). However, the histologic features of the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma. If doubt exists, it is recommended that the investigator should have the slides reviewed by an independent pathologist or, if necessary, the Pathology Co-Chair, prior to entry. Patients may have co-existing Fallopian tube carcinoma in-situ so long as the primary origin of invasive tumor is ovarian or peritoneal. (08/06/07)
- 3.13 Patients must have adequate:
- 3.131 Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/ μ l, equivalent to Common Toxicity Criteria for Adverse Events v3.0 (CTCAE) Grade 1. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. (08/06/07)
- 3.132 Platelets greater than or equal to 100,000/ μ l. (CTCAE Grade 0-1).
- 3.133 Renal function: Creatinine \leq 1.5 x institutional upper limit normal (ULN), CTCAE Grade 1.
- 3.134 Hepatic function:
- 3.1341 Bilirubin less than or equal to 1.5 x ULN (CTCAE Grade 1).

- 3.1342 SGOT and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE Grade 1).
- 3.135 Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1.
- 3.136 Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thrombo-embolus) (08/06/07) and a PTT < 1.2 times the upper limit of normal.
- 3.14 Patients with a GOG Performance Status of 0, 1, or 2.
- 3.15 Patients must be entered between 1 and 12 weeks after initial surgery performed for the combined purpose of diagnosis, staging and cytoreduction.
- 3.16 Patients with measurable (see Section 8.11) and non-measurable (see Section 8.12) disease are eligible. Patients may or may not have cancer-related symptoms.
- 3.17 Patients who have met the pre-entry requirements specified in Section 7.0.
- 3.18 An approved informed consent and authorization permitting release of personal health information must be signed by the patient or guardian.
- 3.19 Patients in this trial may receive ovarian estrogen +/- progestin replacement therapy as indicated at the lowest effective dose(s) for control of menopausal symptoms at any time, but not progestins for management of anorexia while on protocol directed therapy or prior to disease progression. (08/06/07)

3.2 Ineligible Patients

- 3.21 Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly “tumors of low malignant potential”) or recurrent invasive epithelial ovarian cancer treated with surgery only (such as those with stage Ia or Ib low Grade lesions) are not eligible. Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor.
- 3.22 Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
- 3.23 Patients who have received prior chemotherapy for any abdominal or pelvic tumor including neo-adjuvant chemotherapy for their ovarian or primary peritoneal cancer are excluded. Patients may have received prior adjuvant

chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease. (08/06/07)

- 3.24 Patients who have received any **targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy** for management of their epithelial ovarian or peritoneal primary cancer. (06/26/06)
- 3.25 Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: Stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO Grade 3 lesions.
- 3.26 With the exception of non-melanoma skin cancer and other specific malignancies as noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this protocol therapy are excluded. (08/06/07)
- 3.27 Patients with acute hepatitis or active infection that requires parenteral antibiotics.
- 3.28 Patients with serious non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations (see Section 7.1).
- 3.29 Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels.
- 3.30 Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
- 3.31 Patients with clinically significant cardiovascular disease. This includes:
 - 3.311 Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg.
 - 3.312 Myocardial infarction or unstable angina < 6 months prior to registration.
 - 3.313 New York Heart Association (NYHA) Grade II or greater congestive heart failure (Appendix II).